AVITA Medical Inc expected to post a loss of 28 cents a share - Earnings Preview
AVITA Medical Inc
RCEL is expected to show a fall in quarterly revenue when it reports results on November 7 for the period ending September 30 2025The Valencia California California-based company is expected to report a 7.0% decrease in revenue to $18.183 million from $19.55 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for AVITA Medical Inc is for a loss of 28 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AVITA Medical Inc is $5.50, about 34.2% above its last closing price of $3.62
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.25 | -0.25 | -0.38 | Missed | -53.2 |
Mar. 31 2025 | -0.38 | -0.38 | -0.53 | Missed | -37.7 |
Dec. 31 2024 | -0.49 | -0.43 | -0.44 | Missed | -1.6 |
Sep. 30 2024 | -0.44 | -0.44 | -0.62 | Missed | -42.1 |
Jun. 30 2024 | -0.52 | -0.52 | -0.60 | Missed | -15.8 |
Mar. 31 2024 | -0.45 | -0.47 | -0.73 | Missed | -54.3 |
Dec. 31 2023 | -0.36 | -0.37 | -0.28 | Beat | 25.2 |
Sep. 30 2023 | -0.45 | -0.44 | -0.34 | Beat | 23.4 |
This summary was machine generated November 5 at 00:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)